Physician profile
Ankit Rawal
NPI 1891074555
$2,956.45
in general payments reported to CMS, 2019-2025
16 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $119 · 2021: $36.13 · 2022: $477 · 2023: $608 · 2024: $1,066 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673 · Consulting Fee: $375 · Education: $6.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,673.44 |
| Consulting Fee | $375.00 |
| Education | $6.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $718.94 | 2020-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $599.11 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $469.16 | 2019-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $415.38 | 2022-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $140.55 | 2022-2025 | |
| Ardelyx, INC. | $117.03 | 2024-2025 | Ibsrela |
| Mallinckrodt Enterprises LLC | $105.42 | 2019 | |
| Daiichi Sankyo INC. | $83.70 | 2022-2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.81 | 2022-2024 | Jardiance |
| Calliditas Therapeutics US INC. | $53.13 | 2022-2025 | Tarpeyo |
| Amgen INC. | $44.35 | 2023-2025 | Tavneos |
| Aurinia Pharma U.S., INC. | $38.92 | 2022-2023 | Lupkynis |
| Welch Allyn | $36.13 | 2021 | |
| Novartis Pharmaceuticals Corporation | $27.75 | 2025 | |
| Renalytix Ai, INC. | $21.66 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.41 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankit Rawal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.